Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Ivabradine acts by inhibiting the ionic If current that modulates the pacemaker activity of
sinoatrial node cells. The aim of present study is to evaluate the efficacy and safety of
IvabRadine hemisulfate Sustained-release Tablets versus placebo in patients with moderate to
severe chronic systolic heart failure.